GlassScriptPhysician profile
Aaron Slyh
NPI 1922757665
$1,673.60
in general payments reported to CMS, 2019-2025
25 companies · $533 in 2025
The $533 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $282 · 2023: $615 · 2024: $245 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,392.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $453.90 | 2022-2025 | |
| Axsome Therapeutics, INC. | $211.89 | 2023-2025 | Auvelity, Sunosi |
| Corium, LLC | $156.40 | 2023 | Azstarys |
| Almatica Pharma LLC | $120.12 | 2023-2024 | Loreev Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.01 | 2022-2025 | Xifaxan |
| Vanda Pharmaceuticals INC. | $80.47 | 2025 | Hetlioz, Fanapt |
| Lilly USA, LLC | $71.08 | 2022-2023 | Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.48 | 2022-2025 | Caplyta |
| Dexcom, INC. | $49.06 | 2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $47.56 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Otsuka America Pharmaceutical, INC. | $37.37 | 2024-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $34.40 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.09 | 2022-2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.37 | 2024 | |
| Tolmar, INC. | $29.36 | 2025 | Jatenzo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $23.30 | 2023 | Nexletol |
| Collegium Pharmaceutical, INC. | $19.50 | 2025 | Jornay Pm |
| Vertex Pharmaceuticals Incorporated | $19.41 | 2025 | |
| Ironshore Pharmaceuticals INC. | $17.34 | 2024 | |
| Bausch Health US, LLC | $17.06 | 2025 | Wellbutrin, Aplenzin |
| Janssen Pharmaceuticals, INC | $16.89 | 2022 | |
| Pfizer INC. | $14.38 | 2024 | |
| Supernus Pharmaceuticals, INC. | $13.77 | 2025 | Qelbree |
| Novartis Pharmaceuticals Corporation | $13.66 | 2022 | |
| Endogastric Solutions, INC | $11.73 | 2024 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Slyh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.